HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.
The initial focus of the alliance will be Turning Point’s lead drug candidate, repotrectinib, a next-generation kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors that is currently being studied in a registrational Phase 1/2 study (TRIDENT-1). Alliance studies also will include elzovantinib (TPX-0022), a kinase inhibitor targeting MET, CSF1R and SRC, which is currently being studied in a Phase 1 trial of patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1).
The planned focus of the alliance will include monotherapy and potential combinations with other agents – including chemotherapy, immunotherapies and other targeted agents.
"This agreement embodies our commitment to further advancing our innovative macrocyclic programs and complementing our development efforts through collaborative alliances with those who share our vision for breakthrough science," said Homa Yeganegi, Senior Vice President and Global Product Development Lead at Turning Point Therapeutics. "We look forward to working with MD Anderson to strengthen our scientific and clinical understanding of our multi-targeted compounds in several tumor types with the goal of speeding delivery of new cancer treatments to patients."
The alliance brings together MD Anderson's clinical trial infrastructure and expertise with Turning Point's differentiated targeted oncology pipeline. Under the terms of the alliance’s agreement, which spans a five-year period, collaborative preclinical and clinical studies will be conducted in several solid tumors, including non-small cell lung cancers, gastrointestinal malignancies and endocrine cancers.
“There is a major unmet need to develop effective next-generation targeted therapies for cancer patients with oncogene-driven solid tumors, particularly those with mutations that render them resistant to our current therapies,” said John V. Heymach, M.D., Ph.D., Chair of Thoracic/Head & Neck Medical Oncology at MD Anderson. "Our alliance with Turning Point represents an important opportunity to work toward advancing new treatment options for patients using novel inhibitors that target multiple driver mutations with the most characterized resistance patterns in common cancers."
The collaborative studies will be overseen by a joint steering committee. Turning Point will provide funding, study materials and other ongoing support throughout the term of the alliance.
About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 52 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings. It has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
About Turning Point Therapeutics Inc. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer; and TPX-4589 (LM-302), a novel ADC targeting Claudin18.2 which is being studied in a Phase 1 study in gastrointestinal cancers. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding, among other things, Turning Point Therapeutics’ ability to advance its macrocyclic programs and speed delivery of new cancer treatments to patients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics’ business and the other risks described in Turning Point Therapeutics’ filings with the Securities and Exchange Commission (SEC), including its quarterly report on Form 10-Q filed with the SEC on May 10, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact: Adam D. Levy, Ph.D., MBA ir@tptherapeutics.com 858-867-6366
Clayton Boldt, Ph.D. CRBoldt@MDAnderson.org 713-792-9518
Exelixis (NASDAQ: EXEL) and CRISPR Therapeutics (NASDAQ: CRSP) have been able to parlay their specialized knowledge of genetic therapies into share-price growth. While the Fidelity Select Biotech ETF is down more than 22% for the year, these two biotechs have been able to buck that downward trend. Exelixis is a biotech that focuses on genetic therapies to fight difficult-to-treat cancers.
Novavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first commercial product. But the company is still working on younger age group eligibility and boosters with the FDA.
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%. Analysts at Morgan Stanley recently noted that obesity has the potential to become the next blockbuster pharma category, reaching a value of $54 billion in 2030. The main reason for that projection is that treatment trends are showing more of a focus on upstream causes of diabetes and cardiovascular disease, rather than on treating the resulting diseases.
Novavax has shipped 3.2 million doses of its Covid-19 vaccine to federal distribution centers, allowing people to start receiving the shots as soon as Monday, the company said. The doses will be available to people who haven’t yet been vaccinated against the virus following authorization by the Food and Drug Administration earlier this month and an endorsement from the Centers for Disease Control and Prevention on Tuesday. Novavax said doses shipped from its warehouses were received by federal government distribution centers on Friday.
The new COVID-19 variants are more transmissible than ever, but how different do symptoms look compared to a year ago?
The deal marks one of Amazon's most high-profile pushes into health care to date.
The 6-year-old was bitten while at the Bluestem Prairie Open Space near Colorado Springs on July 5 and died Monday.
Dr. Anthony Fauci, chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases is warning of "pandemic fatigue" and what the future holds for COVID-19 vaccinations and boosters. "We're in a pattern now. If somebody says, 'You'll leave when we don't have Covid anymore,' then I will be 105. I think we're going to be living with this," says Dr. Fauci. Here's what he thinks will happen next. Read on—and to ensure your health and the health of
Biotech company Exelixis (NASDAQ: EXEL) is not the most famous name in the industry. If Exelixis can continue beating the market, investors would do well to purchase its shares now. Exelixis' crown jewel, cancer drug Cabometyx, continues to be successful.
The tech giant’s acquisition of primary-care clinics is unlike its previous expansions into groceries, entertainment and advertising.
Two years after the onset of COVID-19 in the U.S., a new vaccine is coming to market -- who will it help?
The 67-year-old woman was airlifted from Portland in the US to Chennai in India for surgery.
J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.
Although we are seeing higher cases within the gay community, monkeypox is not just exclusive to men who have sex with other men.
French experts are recommending that people cut back on processed meats and charcuterie over the risk of colon cancer.
Without obvious signs of contamination like the mold in this jam, consumers use expiration dates to decide whether to keep or throw away food. Ralf Geithe via iStock/Getty ImagesFlorida’s outbreak of listeria has so far led to at least one death, 22 hospitalizations and an ice cream recall since January. Humans get sick with listeria infections, or listeriosis, from eating soil-contaminated food, undercooked meat or dairy products that are raw, or unpasteurized. Listeria can cause convulsions, c
The nine-member Supreme Court voted 5-4 last month to overturn the 1973 judgment known as Roe v. Wade, which established a constitutional right to abortion. A number of companies have simply told their employees that they will pay travel costs for anyone needing abortion and reproductive-health access. YouTube has just broken its silence on a related issue.
Danish biotechnology company Bavarian Nordic said on Friday the European Union's drug regulator had recommended its Imvanex vaccine be approved to also include protection against monkeypox on its label. The European Medicines Agency (EMA) had "adopted a positive opinion recommending that the marketing authorisation for the company's smallpox vaccine, IMVANEX, is extended to include protecting people from monkeypox disease," Bavarian said.
Activists are calling for the release of Tupac Shakur’s stepfather, Mutulu Shakur, from a prison sentence since he is battling a rare form of blood cancer that doctors say is incurable. Shakur has been incarcerated for more than 35 years. He is now 71 and suffering from stage-3 multiple myeloma, a blood cancer that can destroy the bones and kidneys.
The Boston biotech is concentrating its work into a handful of focus areas, including a drug intended to treat WHIM syndrome.